Engineering lymph node homing of ex vivo-expanded human natural killer cells via trogocytosis of the chemokine receptor CCR7.
about
Natural Killer Cells for Immunotherapy - Advantages of the NK-92 Cell Line over Blood NK CellsHuman NK Cell Subsets Redistribution in Pathological Conditions: A Role for CCR7 ReceptorDysregulation of Chemokine/Chemokine Receptor Axes and NK Cell Tissue Localization during DiseasesGraft-versus-Leukemia Effect Following Hematopoietic Stem Cell Transplantation for Leukemia.Valproic acid sensitizes pancreatic cancer cells to natural killer cell-mediated lysis by upregulating MICA and MICB via the PI3K/Akt signaling pathway.A cytokine-delivering polymer is effective in reducing tumor burden in a head and neck squamous cell carcinoma murine model.Enhanced cytotoxicity of natural killer cells following the acquisition of chimeric antigen receptors through trogocytosisAcquisition of activation receptor ligand by trogocytosis renders NK cells hyporesponsive.Revving up Natural Killer Cells and Cytokine-Induced Killer Cells Against Hematological Malignancies.Genetic Manipulation of NK Cells for Cancer Immunotherapy: Techniques and Clinical Implications.Thymus-derived regulatory T cells restrain pro-inflammatory Th1 responses by downregulating CD70 on dendritic cells.Efficient mRNA-Based Genetic Engineering of Human NK Cells with High-Affinity CD16 and CCR7 Augments Rituximab-Induced ADCC against Lymphoma and Targets NK Cell Migration toward the Lymph Node-Associated Chemokine CCL19.Chemokines as novel and versatile reagents for flow cytometry and cell sortingTrial Watch: Adoptive cell transfer for anticancer immunotherapy.Imprinting of lymphocytes with melanoma antigens acquired by trogocytosis facilitates identification of tumor-reactive T cells.Clinical utility of natural killer cells in cancer therapy and transplantation.TLR/NCR/KIR: Which One to Use and When?Umbilical cord blood graft engineering: challenges and opportunities.Engineering Receptor Expression on Natural Killer Cells Through Trogocytosis.CXCL10-induced migration of adoptively transferred human natural killer cells toward solid tumors causes regression of tumor growth in vivo.Microfluidic-based, live-cell analysis allows assessment of NK-cell migration in response to crosstalk with dendritic cells.Targeting the tumor microenvironment to improve natural killer cell-based immunotherapies: On being in the right place at the right time, with resilience.Genetic engineering of human NK cells to express CXCR2 improves migration to renal cell carcinoma.Trace Evidence: Identifying Natural Cancer Killers After the Crime.Leveraging natural killer cells for cancer immunotherapy.Engineering an Injectable Muscle-Specific Microenvironment for Improved Cell Delivery Using a Nanofibrous Extracellular Matrix Hydrogel.mRNA Transfection to Improve NK Cell Homing to Tumors.Microfluidic-Based Live-Cell Analysis of NK Cell Migration In Vitro.Next generation natural killer cells for cancer immunotherapy: the promise of genetic engineering.Viral and Nonviral Engineering of Natural Killer Cells as Emerging Adoptive Cancer Immunotherapies
P2860
Q26751020-007EF5E2-F88E-4C64-BF49-7FA4FB6720D8Q28067468-12DAF658-8A9A-4401-ABFA-AD9254CC5719Q28079140-44156395-3861-4062-928A-9E1CECC3F945Q33770125-562E095F-EB1C-4D61-A1D0-1F82505A31EAQ33825014-74A318F9-CFC8-43B7-9151-B06C18728639Q34205801-A91A9337-4F17-48FF-B6E6-4D33E41D1797Q34338159-51F1DF1A-4C09-459C-B42E-0AC702B7D63EQ35541252-C2AC41DB-7FA5-4908-BB7C-56E0C3292303Q35600095-23590DEA-E128-4EB0-B70F-7D7E479ECA71Q35711209-283C79B9-7246-44A2-8493-570A79144DD8Q35819655-B8DC43CC-752A-470A-8778-E4BF29104F41Q36712346-26B00B86-4A61-45FC-9FB8-DEDBA77E7DE7Q36766798-9767E325-1B6A-4674-B436-556E2964AFE1Q36887833-0C943808-65AF-4A73-8216-6010AF27EE7BQ36973086-A61205C5-E35E-40F3-B817-9E8AA363019BQ38195120-DBEE10B9-D781-4B9B-8144-F2B49D4D98FFQ38200088-042031F8-B2C8-44BC-AA8E-C5A126FF8B3BQ38514503-5336C58F-5737-4FFC-903A-645543674277Q38771091-29D4BC63-2EF1-4C3F-8004-28509733F2E6Q38945158-E34AEE52-91BC-4DD7-B087-6D9980AF10E8Q39171809-EB339E5F-E105-4D20-96C4-181EA77C9409Q39281940-B6EF5DD2-3C33-4337-9C27-D61B945363A1Q41714691-AB750454-F8B4-4E69-89C9-BAE47DCDD627Q42612758-3C329800-EE50-4738-9515-4A785778609DQ43865719-2C3603C9-9381-4B05-829B-BD1F42CA30E9Q46443054-CA444D30-458C-48FB-A2A7-6A4F1EC2FE63Q50853339-8438349A-D55D-47A0-AD39-108A617B4A97Q51332483-FD20A554-6CAB-4B6C-ABE0-56361793D46FQ52615722-355C9776-BC36-4BA4-8559-8DC80BF27E13Q57300237-E70D39A1-B7F9-4563-B442-4CD15BDD660F
P2860
Engineering lymph node homing of ex vivo-expanded human natural killer cells via trogocytosis of the chemokine receptor CCR7.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Engineering lymph node homing ...... f the chemokine receptor CCR7.
@ast
Engineering lymph node homing ...... f the chemokine receptor CCR7.
@en
type
label
Engineering lymph node homing ...... f the chemokine receptor CCR7.
@ast
Engineering lymph node homing ...... f the chemokine receptor CCR7.
@en
prefLabel
Engineering lymph node homing ...... f the chemokine receptor CCR7.
@ast
Engineering lymph node homing ...... f the chemokine receptor CCR7.
@en
P2093
P2860
P1433
P1476
Engineering lymph node homing ...... of the chemokine receptor CCR7
@en
P2093
Anitha Somanchi
Laurence J N Cooper
Srinivas S Somanchi
P2860
P304
P356
10.1182/BLOOD-2011-11-389924
P407
P50
P577
2012-04-12T00:00:00Z